Eli Lilly in Talks to Acquire Psychedelic Drugmaker AtaiBeckley: Bloomberg Report
New Delhi: Eli Lilly is in talks to acquire psychedelic drugmaker AtaiBeckley and a deal could be announced as soon as this week, Bloomberg News reported on Wednesday, citing people familiar with the matter.
AtaiBeckley shares soared 66% in aftermarket trading, while Lilly was flat. AtaiBeckley was up 31% so far this year and had a market value of $1.97 billion as of Wednesday's close, according to LSEG data.
Lilly is negotiating a deal at a premium, Bloomberg News said.
Eli Lilly and AtaiBeckley were not immediately available for comment outside regular business hours.
New York-based AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.
The company's shares received a boost this year after U.S. President Donald Trump ordered health regulators to speed up reviews of psychedelic treatments and increased federal funding for their research.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.